Literature DB >> 27239981

The Prognostic Significance of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Patients With Multiple Myeloma.

Supakanya Wongrakpanich1, Gemlyn George2, Wikrom Chaiwatcharayut2, Sylvia Biso2, Nellowe Candelario2, Varun Mittal2, Sherry Pomerantz2, Gabor Varadi2.   

Abstract

OBJECT: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are simple, inexpensive prognostic markers for various conditions. The objective of this study was to determine the prognostic significance of NLR and PLR in patients with multiple myeloma (MM) in terms of survival.
METHOD: A retrospective chart review study was conducted for 175 patients who met the criterion of diagnosis for MM between January 2004 and September 2014. RESULT: The median age of diagnosis was 69 years. Patients were divided into high and low NLR and PLR groups according to cutoff points from the receiver operating characteristic curve (2.78 and 155.58, respectively). The high NLR and PLR groups were associated with lower albumin level and higher staging. The high NLR group experienced inferior median survival compared with the low NLR group (37 vs. 66 months; log-rank P-value 0.005). However, there was no significant difference in median survival between the high and low PLR groups (45 vs. 62 months; P = 0.077). Multivariate analysis demonstrated that NLR is an independent predictor for OS of MM (HR 2.892; P = 0.009).
CONCLUSION: We conclude that NLR is an independent prognostic factor for OS in MM.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  multiple myeloma; neutrophil-to-lymphocyte ratio; overall survival; platelet-to-lymphocyte ratio; prognostic marker

Mesh:

Substances:

Year:  2016        PMID: 27239981      PMCID: PMC6807214          DOI: 10.1002/jcla.22004

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  28 in total

Review 1.  Multiple myeloma - current issues and controversies.

Authors:  Shaji Kumar
Journal:  Cancer Treat Rev       Date:  2010-05       Impact factor: 12.111

Review 2.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

Review 3.  Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.

Authors:  A J Greenberg; C M Vachon; S V Rajkumar
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 11.528

Review 4.  Neutrophil to lymphocyte ratio and cardiovascular diseases: a review.

Authors:  Tariq Bhat; Sumaya Teli; Jharendra Rijal; Hilal Bhat; Muhammad Raza; Georges Khoueiry; Mustafain Meghani; Muhammad Akhtar; Thomas Costantino
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-01

5.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

Review 6.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

7.  Lymphopenia predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Ji-Feng Feng; Jin-Shi Liu; Ying Huang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

8.  Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma.

Authors:  Ji-Feng Feng; Ying Huang; Jin-Shi Liu
Journal:  Onco Targets Ther       Date:  2013-11-07       Impact factor: 4.147

9.  Predictive contribution of neutrophil/lymphocyte ratio in diagnosis of brucellosis.

Authors:  Serdar Olt; Hasan Ergenç; Seyyid Bilal Açıkgöz
Journal:  Biomed Res Int       Date:  2015-02-03       Impact factor: 3.411

10.  Relationship between platelet-to-lymphocyte ratio and coronary slow flow.

Authors:  Muhammed Oylumlu; Adnan Doğan; Mustafa Oylumlu; Abdülkadir Yıldız; Murat Yüksel; Fethullah Kayan; Celal Kilit; Basri Amasyalı
Journal:  Anatol J Cardiol       Date:  2014-04-08       Impact factor: 1.596

View more
  14 in total

1.  Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma.

Authors:  Yanjie Li; Hujun Li; Wenjing Li; Lijin Wang; Zhiling Yan; Yao Yao; Ruosi Yao; Kailin Xu; Zhenyu Li
Journal:  J Clin Lab Anal       Date:  2016-12-07       Impact factor: 2.352

2.  Clinical and Hematological Predictors for Return of Spontaneous Circulation in Patients With Out-of-Hospital Cardiac Arrest.

Authors:  Chih-Jung Chang; Tse-Hsuan Liou; Wei-Ting Tsai; Ching-Fang Hsu; Wah-Sheng Chong; Jen-Tang Sun; Tzung-Hai Yen; Wen-Chu Chiang; Chih-Chun Chang
Journal:  J Acute Med       Date:  2020-06-01

3.  Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant.

Authors:  Karen Sweiss; Jonathan Lee; Nadim Mahmud; Gregory S Calip; Youngmin Park; Dolores Mahmud; Damiano Rondelli; Pritesh R Patel
Journal:  Bone Marrow Transplant       Date:  2019-09-16       Impact factor: 5.483

4.  Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis.

Authors:  Shidai Mu; Lisha Ai; Fengjuan Fan; Chunyan Sun; Yu Hu
Journal:  Onco Targets Ther       Date:  2018-01-23       Impact factor: 4.147

5.  Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.

Authors:  Ricardo Fernández; Esther Chon
Journal:  J Vet Intern Med       Date:  2018-03-22       Impact factor: 3.333

6.  Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma.

Authors:  Jongheon Jung; Hyewon Lee; Tak Yun; Eunyoung Lee; Hae Moon; Jungnam Joo; Weon Seo Park; Mihong Choi; Jeong-Ok Lee; Jong Seok Lee; Hyeon-Seok Eom
Journal:  Oncotarget       Date:  2017-08-24

7.  Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: A meta-analysis.

Authors:  Qiang Zeng; Zhigang Liu; Qiuyang Li; Ting Liu
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

8.  Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?

Authors:  Serife Solmaz; Ozcan Uzun; Celal Acar; Omur Gokmen Sevindik; Ozden Piskin; Hayri Guner Ozsan; Fatih Demirkan; Bulent Undar; Ahmet Alacacioglu; Mehmet Ali Ozcan; Inci Alacacioglu
Journal:  J Lab Physicians       Date:  2018 Oct-Dec

9.  High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling.

Authors:  A Romano; N L Parrinello; V Simeon; F Puglisi; P La Cava; C Bellofiore; C Giallongo; G Camiolo; F D'Auria; V Grieco; F Larocca; A Barbato; D Cambria; E La Spina; D Tibullo; G A Palumbo; C Conticello; P Musto; F Di Raimondo
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

Review 10.  Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.

Authors:  Liu Zhaoyun; Fu Rong
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.